The MTL-CEBPA treated group had significant upregulation of CEBPA mRNA (1.74 fold, p = 0.0012) and the tumor regressing subgroup of anti-PD-1+MTL-CEBPA had a high expression of CEBPA mRNA (8.69 fold, p < 0.0001) (Figure 5b). This evidence concerns the gene CEBPA and neoplasm.